UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Envista Holdings Co. (NYSE:NVST – Free Report) by 0.8% in the third quarter, according to its most recent filing with the SEC. The fund owned 425,502 shares of the company’s stock after acquiring an additional 3,199 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.25% of Envista worth $8,408,000 as of its most recent SEC filing.
A number of other hedge funds also recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Envista in the third quarter valued at about $31,000. GAMMA Investing LLC increased its position in shares of Envista by 69.8% in the third quarter. GAMMA Investing LLC now owns 1,766 shares of the company’s stock valued at $35,000 after acquiring an additional 726 shares during the period. Huntington National Bank increased its position in shares of Envista by 97.8% in the third quarter. Huntington National Bank now owns 1,919 shares of the company’s stock valued at $38,000 after acquiring an additional 949 shares during the period. Blue Trust Inc. increased its position in shares of Envista by 69.7% in the third quarter. Blue Trust Inc. now owns 1,957 shares of the company’s stock valued at $39,000 after acquiring an additional 804 shares during the period. Finally, Allspring Global Investments Holdings LLC increased its position in shares of Envista by 50.8% in the third quarter. Allspring Global Investments Holdings LLC now owns 2,161 shares of the company’s stock valued at $43,000 after acquiring an additional 728 shares during the period.
Envista Trading Up 0.6 %
Shares of NYSE NVST opened at $20.01 on Tuesday. The firm’s 50 day moving average price is $19.98 and its 200-day moving average price is $18.37. The company has a market cap of $3.44 billion, a PE ratio of -2.58, a P/E/G ratio of 2.77 and a beta of 1.31. Envista Holdings Co. has a 52-week low of $15.15 and a 52-week high of $25.64. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.77 and a current ratio of 2.08.
Wall Street Analysts Forecast Growth
NVST has been the topic of a number of analyst reports. Mizuho initiated coverage on shares of Envista in a research report on Wednesday, December 4th. They issued an “underperform” rating and a $20.00 price objective on the stock. Robert W. Baird boosted their price objective on shares of Envista from $17.00 to $22.00 and gave the company a “neutral” rating in a research report on Thursday, October 31st. Evercore ISI boosted their price target on shares of Envista from $18.00 to $23.00 and gave the company an “outperform” rating in a research report on Monday, September 23rd. Wells Fargo & Company initiated coverage on shares of Envista in a research report on Tuesday, October 8th. They set an “equal weight” rating and a $20.00 price target on the stock. Finally, Stifel Nicolaus boosted their price target on shares of Envista from $18.00 to $21.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $20.65.
Get Our Latest Research Report on NVST
About Envista
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.
Featured Articles
- Five stocks we like better than Envista
- Consumer Staples Stocks, Explained
- How to Master Trading Discipline: Overcome Emotional Challenges
- Do ETFs Pay Dividends? What You Need to Know
- Does China Investigation Change NVIDIA’s Outlook; Yes, No, Maybe?
- What Are Dividend Champions? How to Invest in the Champions
- Is Marvell Technology Chipping Away at NVIDIA’s Market Lead?
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.